EUVIMEDEUVIMED entdecken
Crossref

Stimuli-responsive magnetic silica-poly-lactic-co-glycolic acid hybrid nanoparticles for targeted cancer chemo-immunotherapy

Anuradha Gupta, Karishma Niveria, Hitesh Harsukhbhai Chandpa, Mamta Singh, Vikas Kumar, Amulya Kumar Panda, Jairam Meena iD

Drug Delivery and Translational Research · 2024

DOI: 10.1007/s13346-024-01521-0 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Delivery and Translational Research, 2024. Verfasst von Anuradha Gupta und 6 weiteren Autor:innen. Beteiligte Einrichtung: School of Material Science and Technology, Indian Institute of Technology (BHU) Varanasi, Varanasi, 221005, India. Hauptthemen laut MEDLINE: Silicon Dioxide, Paclitaxel, B7-H1 Antigen, Polylactic Acid-Polyglycolic Acid Copolymer. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 39 Literaturangaben. Gefördert von: Indian Council of Medical Research, SERB DST.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chemotherapy and immunotherapy are two important modalities in cancer management. However, due to multiple reasons, a monotherapy is only partially effective. Hence, if used concurrently in targeted and stimuli-responsive manner, it could have been superior therapeutically. To facilitate co-delivery of chemotherapeutic and immunotherapeutic agent to the target cancer cells, engineered nanoparticles, i.e., a pH-responsive polymer PLGA-coated magnetic silica nanoparticles (Fe3O4-SiO2-PLGA-PDA-PTX-siRNA NPs) encapsulating paclitaxel (PTX) and siRNA against programmed cell death ligand-1 (PD-L1) are synthesized and characterized. Developed nanoparticles demonstrated pH-sensitive sustained drug release up to 10 days. In vitro 4T1 cell line studies showed efficient cellular uptake, PD-L1 gene downregulation, and apoptosis. Further, in vivo efficacy studies carried out in the mice model demonstrated a significant reduction of tumor growth following treatment with dual-Fe3O4-SiO2-PLGA-PDA-PTX-siRNA NPs as compared with monotherapy with Fe3O4-SiO2-PLGA-PDA-PTX NPs. The high therapeutic efficacy observed with dual-Fe3O4-SiO2-PLGA-PDA-PTX-siRNA NPs was mainly due to the cytotoxic effect of PTX combined with targeted silencing of the gene of interest, i.e., PD-L1, which in turn improve CD8+ T cell-mediated cancer cell death as evident with increased proliferation of CD8+ T cells in co-culture experiments. Thereby, dual-Fe3O4-SiO2-PLGA-PDA-PTX-siRNA NPs may have a promising anti-cancer treatment potential against breast cancer; however, the beneficial effects of dual loading of PTX + PD-L1 siRNA may be corroborated against other cancer models such as lung and colorectal cancer models as well as in clinical trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Silicon DioxidePaclitaxelB7-H1 AntigenPolylactic Acid-Polyglycolic Acid CopolymerImmunotherapyRNA, Small InterferingMice, Inbred BALB CAnimalsCell Line, TumorFemaleMiceDrug LiberationMagnetite NanoparticlesApoptosisNanoparticlesAntineoplastic Agents, PhytogenicHydrogen-Ion ConcentrationHumansDrug Carriers

Stichwörter der Autor:innen

ImmunotherapyMagnetic- silica nanoparticlesPaclitaxelPoly-lactic co-glycolic acid (PLGA)Polydopamine (PDA)Programmed cell death ligand-1 (PD-L1)Small-interfering RNA (siRNA)

Substanzen

Silicon DioxidePaclitaxelB7-H1 AntigenPolylactic Acid-Polyglycolic Acid CopolymerRNA, Small InterferingMagnetite NanoparticlesAntineoplastic Agents, PhytogenicDrug Carriers

Autor:innen und Institutionen

  • School of Material Science and Technology, Indian Institute of Technology (BHU) Varanasi, Varanasi, 221005, India.
  • Product Development Cell, National Institute of Immunology, Aruna Asaf Ali Marg, New Delhi, 110067, India.
  • Nanobiotech Lab, Department of Zoology, Kirori Mal College, University of Delhi, Delhi, 110007, India.
  • ImmunoEngineering and Therapeutics Laboratory, Department of Pharmaceutical Engineering and Technology, Indian Institute of Technology (BHU) Varanasi, Varanasi, 221005, India.
  • Cell Biology Lab, Kusuma School of Biological Sciences, Indian Institute of Technology, New Delhi, 110067, India.
  • Product Development Cell, National Institute of Immunology, Aruna Asaf Ali Marg, New Delhi, 110067, India. jairam.phe@itbhu.ac.in.

ORCID-Profile: Jairam Meena

Förderung

  • Indian Council of Medical Research
  • SERB DST

Zitieren

APA

Gupta, A., Niveria, K., Chandpa, H. H., Singh, M., Kumar, V., Panda, A. K., & Meena, J. (2024). Stimuli-responsive magnetic silica-poly-lactic-co-glycolic acid hybrid nanoparticles for targeted cancer chemo-immunotherapy. Drug Delivery and Translational Research. https://doi.org/10.1007/s13346-024-01521-0

Vancouver

Gupta A, Niveria K, Chandpa HH, Singh M, Kumar V, Panda AK, et al. Stimuli-responsive magnetic silica-poly-lactic-co-glycolic acid hybrid nanoparticles for targeted cancer chemo-immunotherapy. Drug Delivery and Translational Research. 2024. doi:10.1007/s13346-024-01521-0

BibTeX
@article{Gupta2024,
  author = {Gupta, Anuradha and Niveria, Karishma and Chandpa, Hitesh Harsukhbhai and Singh, Mamta and Kumar, Vikas and Panda, Amulya Kumar and Meena, Jairam},
  title = {Stimuli-responsive magnetic silica-poly-lactic-co-glycolic acid hybrid nanoparticles for targeted cancer chemo-immunotherapy},
  journal = {Drug Delivery and Translational Research},
  year = {2024},
  doi = {10.1007/s13346-024-01521-0}
}
Kostenlos starten →